- Home
- BMGL vs NSPR Comparison
BMGL vs NSPR Comparison
Compare BMGL & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMGL
- NSPR
- Stock Information
- Founded
- BMGL 2001
- NSPR 2005
- Country
- BMGL Singapore
- NSPR United States
- Employees
- BMGL N/A
- NSPR N/A
- Industry
- BMGL
- NSPR Medical/Dental Instruments
- Sector
- BMGL
- NSPR Health Care
- Exchange
- BMGL NYSE
- NSPR Nasdaq
- Market Cap
- BMGL 78.3M
- NSPR 79.7M
- IPO Year
- BMGL 2025
- NSPR N/A
- Fundamental
- Price
- BMGL $4.77
- NSPR $2.56
- Analyst Decision
- BMGL
- NSPR Strong Buy
- Analyst Count
- BMGL 0
- NSPR 2
- Target Price
- BMGL N/A
- NSPR $4.75
- AVG Volume (30 Days)
- BMGL 78.2K
- NSPR 47.5K
- Earning Date
- BMGL 01-01-0001
- NSPR 05-09-2025
- Dividend Yield
- BMGL N/A
- NSPR N/A
- EPS Growth
- BMGL 16.23
- NSPR N/A
- EPS
- BMGL 0.09
- NSPR N/A
- Revenue
- BMGL $7,428,776.00
- NSPR $7,027,000.00
- Revenue This Year
- BMGL N/A
- NSPR $28.93
- Revenue Next Year
- BMGL N/A
- NSPR $172.18
- P/E Ratio
- BMGL $50.27
- NSPR N/A
- Revenue Growth
- BMGL 3.32
- NSPR 12.96
- 52 Week Low
- BMGL $3.63
- NSPR $2.07
- 52 Week High
- BMGL $5.50
- NSPR $3.80
- Technical
- Relative Strength Index (RSI)
- BMGL N/A
- NSPR 49.83
- Support Level
- BMGL N/A
- NSPR $2.40
- Resistance Level
- BMGL N/A
- NSPR $2.79
- Average True Range (ATR)
- BMGL 0.00
- NSPR 0.16
- MACD
- BMGL 0.00
- NSPR 0.02
- Stochastic Oscillator
- BMGL 0.00
- NSPR 60.42
About BMGL BASEL MEDICAL GROUP LTD
Basel Medical Group Ltd provides general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. Key revenue is generated from Singapore.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.